Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

NCT01762592 is registered in ClinicalTrials.gov with Heidelberg Pharma AG as lead sponsor.

NCT NCT01762592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01762592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Lead sponsor
Heidelberg Pharma AG
Phase
Phase 3
Overall status
Withdrawn
Start date
December 31, 2017
Completion date
December 31, 2019
Enrollment
0 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma